forms the therapy of chronic neurodegenerative pathologies especially of the cns such as parkinson disease alzheimer disease as well as less serious cognitive deficiency can be advantageously treated with the compounds of the present invention to a prolonged and cyclically repeated treatment with the compounds of the present invention patients affected by cutaneous and collagen pathologies are also subjected these pathologies being associated to a premature aging due both to genetic and environmental causes or in any case connected to peroxidative and inflammatory phenomena such as exanthematous lupus erythematosus lichen psoriasis dermatitis seborrheica acne eczema and pathologies having a vital etiology such as corneal herpes simplex and cytomegalovirus retinal infection as well as phenomena due to the alteration of sebaceous and sudorifearous glands secretion including bromhidrosis which can have a regression thanks to the antiperoxidant anti inflammatory effect for these pathologies both the therapeutic use by oral and parenteral intravenous intramuscular and subcutaneous systemic route topical cutaneous and corneal transdermic and intradermic route is encompassed the necessary dose to have the therapeutic effect depends on the considered pathology the weight and age of the patient preferred therapeutic ranges are comprised between 1 and 100 mg kg preferably between 5 and 30 mg kg for varying periods and in any case not.